Sphere Fluidics expands into additional facility
McClintock Building, Granta Park.
New offices at leading science hub support the company’s rapid growth following recent investment.
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, has opened a new office space at Granta Park in Cambridgeshire, UK. The new facilities support the company’s accelerated expansion and accommodate its plans for further growth.
Sphere Fluidics recently closed a $4.8 million (£3.7 million) funding round, enabling it to hire 10 new staff to expand commercial capabilities and facilitate service and support for its Cyto-Mine Single Cell Analysis System. Sphere Fluidics sales, marketing, finance and operations teams join the specialist skills pool at Granta Park, one of the UK’s leading life-science research parks, positioned within the Cambridge Science Cluster, taking 1,038 sq. ft in the McClintock Building. The Park is home to over 2,500 people and multiple organizations, placing the company in close proximity to high-quality research and commercialization activity, and opening up the opportunity for further collaborations with potential partners, researchers and suppliers based on the campus.
Sphere Fluidics’ new facilities at Granta Park are in addition to its offices at Babraham Research Campus, Cambridgeshire, UK and Monmouth Junction, New Jersey, USA. The company also has an established network of international distributors in Japan, France, China, Switzerland, Germany, Austria, Benelux, Australia, Scandinavia and Korea.
Rob Treanor, Director of Operations, Sphere Fluidics, commented: “Recent investment has enabled Sphere Fluidics to accelerate its plans to expand commercial and scientific activities and we are now raising further funding to invest in more new hires and increase our presence in not only the UK but also, the US. It is vital that we are positioned in locations with a flexible and innovative network and look forward to joining the collaborative culture at Granta Park to support these growth projections.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.